Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology granted an inducement award to one new employee, who was hired in June 2024....
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma's Board of Directors approved the...
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting....
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting....
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index....
Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe....
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org....
Puma Biotechnology (PBYI) reports narrower-than-expected first-quarter 2024 loss. The company maintains its revenue guidance for 2024....
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Chief Ex...
